Hans Berger Clinic of Neurology, University Hospital Jena, Erlanger Allee 101, 07747 Jena, Germany.
Cell Tissue Res. 2012 Jul;349(1):363-74. doi: 10.1007/s00441-012-1335-6. Epub 2012 Feb 23.
Visual impairment severely affects the quality of life of patients and their families and is also associated with a deep economic impact. The most common pathologies responsible for visual impairment and legally defined blindness in developed countries include age-related macular degeneration, glaucoma and diabetic retinopathy. These conditions share common pathophysiological features: dysfunction and loss of retinal neurons. To date, two main approaches are being taken to develop putative therapeutic strategies: neuroprotection and cell replacement. Cell replacement is a novel therapeutic approach to restore visual capabilities to the degenerated adult neural retina and represents an emerging field of regenerative neurotherapy. The discovery of a population of proliferative cells in the mammalian retina has raised the possibility of harnessing endogenous retinal stem cells to elicit retinal repair. Furthermore, the development of suitable protocols for the reprogramming of differentiated somatic cells to a pluripotent state further increases the therapeutic potential of stem-cell-based technologies for the treatment of major retinal diseases. Stem-cell transplantation in animal models has been most effectively used for the replacement of photoreceptors, although this therapeutic approach is also being used for inner retinal pathologies. In this review, we discuss recent advances in the development of cell-replacement approaches for the treatment of currently incurable degenerative retinal diseases.
视力障碍严重影响患者及其家庭的生活质量,也会造成严重的经济影响。在发达国家,导致视力障碍和法定失明的最常见疾病包括年龄相关性黄斑变性、青光眼和糖尿病视网膜病变。这些疾病具有共同的病理生理特征:视网膜神经元功能障碍和丧失。目前,正在采取两种主要方法来开发潜在的治疗策略:神经保护和细胞替代。细胞替代是一种恢复退化成人神经视网膜视觉能力的新型治疗方法,代表了再生神经治疗的一个新兴领域。在哺乳动物视网膜中发现了一群增殖细胞,这使得利用内源性视网膜干细胞来引发视网膜修复成为可能。此外,为分化的体细胞核重编程为多能状态而开发的合适方案进一步增加了基于干细胞的技术治疗主要视网膜疾病的治疗潜力。干细胞移植在动物模型中已被最有效地用于替代光感受器,尽管这种治疗方法也被用于治疗内视网膜疾病。在这篇综述中,我们讨论了用于治疗目前无法治愈的退行性视网膜疾病的细胞替代方法的最新进展。